Veracyte Net Worth
Veracyte Net Worth Breakdown | VCYT |
Veracyte Net Worth Analysis
Veracyte's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Veracyte's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Veracyte's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Veracyte's net worth analysis. One common approach is to calculate Veracyte's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Veracyte's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Veracyte's net worth. This approach calculates the present value of Veracyte's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Veracyte's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Veracyte's net worth. This involves comparing Veracyte's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Veracyte's net worth relative to its peers.
Enterprise Value |
|
To determine if Veracyte is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Veracyte's net worth research are outlined below:
| Veracyte generated a negative expected return over the last 90 days | |
| Veracyte is unlikely to experience financial distress in the next 2 years | |
| Veracyte has a strong financial position based on the latest SEC filings | |
| Over 99.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Veracyte Inc Stock Price Down 4.21 percent on Jul 18 |
Veracyte uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Veracyte. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Veracyte's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Veracyte Target Price Consensus
Veracyte target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Veracyte's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 11 | Strong Buy |
Most Veracyte analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Veracyte stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Veracyte, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationVeracyte Target Price Projection
Veracyte's current and average target prices are 23.51 and 40.89, respectively. The current price of Veracyte is the price at which Veracyte is currently trading. On the other hand, Veracyte's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On Veracyte Target Price
Know Veracyte's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Veracyte is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Veracyte backward and forwards among themselves. Veracyte's institutional investor refers to the entity that pools money to purchase Veracyte's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2025-03-31 | 1.9 M | Driehaus Capital Management Llc | 2025-03-31 | 1.4 M | Gw&k Investment Management, Llc | 2025-03-31 | 1.3 M | Nuveen Asset Management, Llc | 2024-12-31 | 1.2 M | Bank Of America Corp | 2025-03-31 | 1.2 M | Nuveen, Llc | 2025-03-31 | 1.1 M | Goldman Sachs Group Inc | 2025-03-31 | 1 M | Northern Trust Corp | 2025-03-31 | 1 M | First Trust Advisors L.p. | 2025-03-31 | 1 M | Vanguard Group Inc | 2025-03-31 | 8.3 M | Blackrock Inc | 2025-03-31 | 7.5 M |
Follow Veracyte's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.84 B.Market Cap |
|
Project Veracyte's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.05 | 0.06 | |
| Return On Capital Employed | 0.01 | 0.01 | |
| Return On Assets | 0.02 | 0.02 | |
| Return On Equity | 0.02 | 0.02 |
When accessing Veracyte's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Veracyte's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Veracyte's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Veracyte's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Veracyte. Check Veracyte's Beneish M Score to see the likelihood of Veracyte's management manipulating its earnings.
Evaluate Veracyte's management efficiency
Veracyte has return on total asset (ROA) of 0.0194 % which means that it generated a profit of $0.0194 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0286 %, meaning that it created $0.0286 on every $100 dollars invested by stockholders. Veracyte's management efficiency ratios could be used to measure how well Veracyte manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to 0.06 in 2025. Return On Capital Employed is likely to gain to 0.01 in 2025. At this time, Veracyte's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 1.4 B in 2025, whereas Non Current Liabilities Other is likely to drop slightly above 923.4 K in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 15.38 | 16.14 | |
| Tangible Book Value Per Share | 4.29 | 2.56 | |
| Enterprise Value Over EBITDA | 57.73 | 60.61 | |
| Price Book Value Ratio | 2.58 | 2.45 | |
| Enterprise Value Multiple | 57.73 | 60.61 | |
| Price Fair Value | 2.58 | 2.45 | |
| Enterprise Value | 2.8 B | 3 B |
The strategic vision of Veracyte management plays a critical role in its financial performance. By evaluating this vision, we provide insights into the stock's growth potential.
Enterprise Value Revenue 3.5821 | Revenue | Quarterly Revenue Growth 0.182 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Veracyte insiders, such as employees or executives, is commonly permitted as long as it does not rely on Veracyte's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Veracyte insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Veracyte Corporate Filings
F4 | 23rd of June 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 18th of June 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 6th of June 2025 Other Reports | ViewVerify | |
| 14th of May 2025 Other Reports | ViewVerify |
Veracyte Earnings Estimation Breakdown
The calculation of Veracyte's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Veracyte is estimated to be 0.324825 with the future projection ranging from a low of 0.2975 to a high of 0.3475. Please be aware that this consensus of annual earnings estimates for Veracyte is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.30 Lowest | Expected EPS | 0.35 Highest |
Veracyte Earnings Projection Consensus
Suppose the current estimates of Veracyte's value are higher than the current market price of the Veracyte stock. In this case, investors may conclude that Veracyte is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Veracyte's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 11 | 20.91% | 0.0 | 0.324825 | 0.42 |
Veracyte Earnings per Share Projection vs Actual
Actual Earning per Share of Veracyte refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Veracyte predict the company's earnings will be in the future. The higher the earnings per share of Veracyte, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Veracyte Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Veracyte, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Veracyte should always be considered in relation to other companies to make a more educated investment decision.Veracyte Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Veracyte's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 | ||
2025-05-05 | 2025-03-31 | -0.17 | 0.31 | 0.48 | 282 | ||
2025-02-20 | 2024-12-31 | 0.2571 | 0.36 | 0.1029 | 40 | ||
2024-11-06 | 2024-09-30 | 0.03 | 0.19 | 0.16 | 533 | ||
2024-08-06 | 2024-06-30 | -0.02 | 0.07 | 0.09 | 450 | ||
2024-05-07 | 2024-03-31 | -0.16 | -0.02 | 0.14 | 87 | ||
2024-02-22 | 2023-12-31 | -0.09 | -0.39 | -0.3 | 333 | ||
2023-11-07 | 2023-09-30 | -0.15 | -0.41 | -0.26 | 173 | ||
2023-08-08 | 2023-06-30 | -0.15 | -0.12 | 0.03 | 20 | ||
2023-05-04 | 2023-03-31 | -0.13 | -0.11 | 0.02 | 15 | ||
2023-02-22 | 2022-12-31 | -0.15 | -0.05 | 0.1 | 66 | ||
2022-11-02 | 2022-09-30 | -0.25 | -0.12 | 0.13 | 52 | ||
2022-08-02 | 2022-06-30 | -0.22 | -0.13 | 0.09 | 40 | ||
2022-05-03 | 2022-03-31 | -0.24 | -0.2 | 0.04 | 16 | ||
2022-02-28 | 2021-12-31 | -0.16 | -0.15 | 0.01 | 6 | ||
2021-11-09 | 2021-09-30 | -0.16 | -0.2 | -0.04 | 25 | ||
2021-07-29 | 2021-06-30 | -0.25 | -0.13 | 0.12 | 48 | ||
2021-05-10 | 2021-03-31 | -0.12 | -0.11 | 0.01 | 8 | ||
2021-02-17 | 2020-12-31 | -0.11 | -0.14 | -0.03 | 27 | ||
2020-11-02 | 2020-09-30 | -0.21 | -0.08 | 0.13 | 61 | ||
2020-07-30 | 2020-06-30 | -0.24 | -0.22 | 0.02 | 8 | ||
2020-05-06 | 2020-03-31 | -0.2 | -0.24 | -0.04 | 20 | ||
2020-02-25 | 2019-12-31 | -0.07 | -0.15 | -0.08 | 114 | ||
2019-10-22 | 2019-09-30 | -0.07 | -0.02 | 0.05 | 71 | ||
2019-07-30 | 2019-06-30 | -0.1 | -0.05 | 0.05 | 50 | ||
2019-04-30 | 2019-03-31 | -0.1 | -0.05 | 0.05 | 50 | ||
2019-02-25 | 2018-12-31 | -0.15 | -0.08 | 0.07 | 46 | ||
2018-10-29 | 2018-09-30 | -0.24 | -0.12 | 0.12 | 50 | ||
2018-07-23 | 2018-06-30 | -0.27 | -0.18 | 0.09 | 33 | ||
2018-05-01 | 2018-03-31 | -0.25 | -0.27 | -0.02 | 8 | ||
2018-02-27 | 2017-12-31 | -0.2 | -0.24 | -0.04 | 20 | ||
2017-11-06 | 2017-09-30 | -0.23 | -0.21 | 0.02 | 8 | ||
2017-07-31 | 2017-06-30 | -0.25 | -0.22 | 0.03 | 12 | ||
2017-05-03 | 2017-03-31 | -0.25 | -0.24 | 0.01 | 4 | ||
2017-03-01 | 2016-12-31 | -0.26 | -0.14 | 0.12 | 46 | ||
2016-11-03 | 2016-09-30 | -0.36 | -0.2 | 0.16 | 44 | ||
2016-08-03 | 2016-06-30 | -0.33 | -0.4 | -0.07 | 21 | ||
2016-05-05 | 2016-03-31 | -0.35 | -0.36 | -0.01 | 2 | ||
2016-03-10 | 2015-12-31 | -0.3 | -0.29 | 0.01 | 3 | ||
2015-11-05 | 2015-09-30 | -0.33 | -0.32 | 0.01 | 3 | ||
2015-08-13 | 2015-06-30 | -0.31 | -0.34 | -0.03 | 9 | ||
2015-05-14 | 2015-03-31 | -0.37 | -0.34 | 0.03 | 8 | ||
2015-03-19 | 2014-12-31 | -0.33 | -0.36 | -0.03 | 9 | ||
2014-11-13 | 2014-09-30 | -0.35 | -0.37 | -0.02 | 5 | ||
2014-08-13 | 2014-06-30 | -0.33 | -0.31 | 0.02 | 6 | ||
2014-05-09 | 2014-03-31 | -0.3 | -0.32 | -0.02 | 6 | ||
2014-03-18 | 2013-12-31 | -0.38 | -0.42 | -0.04 | 10 |
Veracyte Corporate Management
| Robert Brainin | Executive Officer | Profile | |
| John Leite | Chief Business | Profile | |
| Annie McGuire | Sr Counsel | Profile | |
| Tracy Morris | VP Communications | Profile |
Additional Tools for Veracyte Stock Analysis
When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.